BA 1301
Alternative Names: BA-1301; Claudin 18.2 ADC - Shandong Boan Biotechnology; PR-301Latest Information Update: 09 Sep 2025
At a glance
- Originator Shandong Boan Biotechnology
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Aug 2025 BA 1301 receives Orphan Drug status for Gastric cancer in USA , prior to August 2025
- 28 Aug 2025 BA 1301 receives Orphan Drug status for Pancreatic cancer in USA, prior to August 2025
- 11 Jan 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in China (IV) (NCT06927349) (Shandong Boan Biotechnology pipeline, August 2023)